This review concluded that ropinirole improved sleep quantity and adequacy and lessened sleep disturbance and daytime somnolence in patients with moderate to severe primary restless leg syndrome. The authors acknowledged a number of limitations of their review and the conclusions should be treated with some caution.
Study selection
Randomised controlled trials (RCTs) that evaluated the impact of ropinirole on sleep in patients with restless legs syndrome compared to placebo were eligible for inclusion. Included studies had to use the Medical Outcomes Study (MOS) sleep scale over at least 12 weeks or the Clinical Global Impression-Improvement (CGI-I) scale to assess sleep outcomes. Studies designed to assess maintenance treatment or long-term safety were excluded. Studies where ropinirole was an adjunct treatment were excluded.
Included studies were restricted to those of moderate to very severe primary restless leg syndrome requiring treatment only at night. Mean age of participants was approximately 54 years. The proportion of males was 37%. Most participants reported risk factors for sleep disturbance (alcohol use, caffeine use, comorbid conditions and concomitant drugs). Most participants were recruited in USA and UK.
The authors did not state how many reviewers performed the study selection.
Assessment of study quality
Only double-blinded RCTs were included in the review; the authors did not report that they used a systematic quality assessment or checked the integrity of individual patient data (IPD).
Data extraction
Individual patient data were obtained for eligible RCTs. The review concentrated on four of the six domains of the MOS sleep scale (quantity, adequacy, disturbance of sleep and daytime somnolence); three of these were converted to a scale from zero to 100. CGI-I was considered a secondary outcome. Mean changes from baseline in sleep scores were calculated. Last observation carried forward was used if patients did not complete 12 week assessments.
The authors did not report how many reviewers performed data extraction.
Methods of synthesis
For primary analysis of MOS sleep domains, a mixed-effects analysis of covariance was used. For secondary analysis of the proportion of patients classified as responders (CGI-I), logistic regression was used. Changes in sleep duration from baseline at 12 weeks between ropinirole and placebo were calculated along with 98.75% confidence intervals (CI) for intention to treat (ITT) and per protocol populations. Age, gender and comorbid conditions were controlled for in the analyses. Changes in sleep scale scores and the proportion of patients rated as responders on the CGI-I scale, along with adjusted odds ratio and 95% CI, were reported. 14/10/2009 Date abstract record published 29/06/2011 Record Status This is a critical abstract of a systematic review that meets the criteria for inclusion on DARE. Each critical abstract contains a brief summary of the review methods, results and conclusions followed by a detailed critical assessment on the reliability of the review and the conclusions drawn.
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